Piśmiennictwo:

1. de Rijk MC, Launer LJ, Berger K et al. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 (Suppl 5):S21-S23.
2. Koller WC, O’Hara R, Weiner W et al. Relationship of aging to Parkinson’s disease. Adv Neurol 1987; 45:317-321.
3. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003;18:19-31.
4. Marioka S, Sakata K, Yoshida S et al. Incidence of Parkinson’s disease in Wakayama, Japan. J Epidemiol 2002;12:403-407.
5. Friedman A. Epidemiologia. [W:] Friedman A, red. Choroba Parkinsona, mechanizmy, rozpoznawanie, leczenie. Lublin: Wydawnictwo Czelej; 2005, str.1-5.
6. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134.
7. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen –Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Ageing 2003;24:197-211.
8. Eriksen JL, Wszołek Z, Petrucelli L. Molecular pathogenesis of Parkinson’s Disease. Arch Neurol 2005;62:353-357.
9. Dawson TM, Dawson VL. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 2003;111:145-151.
10. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 2004;56: 149-162.
11. Shen J, Cookson MR. Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004; 43:301-304.
12. Kłodowska –Duda G, Jasińska-Myga B, Safranow K, Boczarska-Jedynak M, Opala G. Wpływ czynników środowiskowych może zależeć od wieku zachorowania na chorobę Parkinsona. Neurol Neurochir Pol 2006; 39:445-450.
13. Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committeereport: SIC Task Force appraisal of clinical diagnosis criteria for Parkinsonian disorders. Mov Disord 2003;18:467-486.
14. Campos-Sousa RN, Quagliato E, da Silva BB, de Carvahlo RM Jr, Ribeiro SC, de Carvalho DF. Urinary symptoms in Parkinson’s disease prevalence and associated factors. Arq Neuropsiquiatr 2003; 61:359-363.
15. Allocock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;75:1470-1471.
16. Bassotti G, Maggio D, Battaglia E et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Psychiatry 2000; 68:768-770.
17. Leopold NA, Kagel MC. Pharyngo-esophageal dysphagia in Parkinson’s disease. Dysphagia 1997;12:11-20.
18. Double KL, Rowe DB, Hayes M et al. Identifying the pattern of olfactory deficits in Parkinson’s disease using the brief smell identification test. Arch Neurol 2003;60:545-549.
19. Poewe W. Psychosis in Parkinson’s disease. Mov Disord 2003;18(Suppl 6):S80-S87.
20. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:187-196.
21. Ponsen MM, Stoffers D, Booji J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004;56:173-181.
22. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder : a register study. Acta Psychiatr Scand 2001;104:380-386.
23. Leentjens AF, Van Den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18: 414-418.
24. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16:622-630.
25. Abott RD, Ross W, White LR et al. Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003; 250(Suppl 3):301-309.
26. Potulska A, Friedman A, Królicki L, Spychała A. Swallowing disorders in Parkinson’s disease. Parkinsonism Rel Disord 2003;9:349-353.
27. Abott RD, Ross GW, White LR et al. Excessive daytime sleepiness and the future risk of Parkinson’s disease (abstract). Mov Disord 2005; 20 (Suppl 10): S101.
28. The Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351:2498-2508.
29. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000; 47(Suppl 1):S60-S69.
30. Friedman A. Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 1994;89:258-261.
31. Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985;232:29-31.
32. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314.
33. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson’s disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
34. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in Levodopa-treated patients with Parkinson’s disease and motor fluctuations: the PRESTO Study. Arch Neurol 2005;62:241-48.
35. The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
36. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson’s disease: an evidence-based comparison. Drugs Aging 2003;20:847-855.
37. Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-304.
38. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003;60:1721-1728.